{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:47:16Z","timestamp":1772160436309,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,6,29]],"date-time":"2012-06-29T00:00:00Z","timestamp":1340928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Paracetamol is commonly prescribed for first\u2010line symptomatic treatment in patients with osteoarthritis and aspirin is often co\u2010administered for cardiovascular prophylaxis. It is not known if an interaction exists between aspirin and paracetamol in regards to gastroduodenal mucosal injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate whether or not co\u2010administered aspirin with paracetamol results in an increased rate of endoscopic gastroduodenal mucosal injury as compared to either agent alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this prospective, double\u2010blind, randomised, three\u2010arm, placebo\u2010 and active\u2010controlled, parallel\u2010group pilot study healthy adult subjects (18\u201375\u00a0years old) with a normal baseline trans\u2010nasal oesophagogastroduodenoscopy (\n                      <jats:styled-content style=\"fixed-case\">TN<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">EGD<\/jats:styled-content>\n                      ), received oral paracetamol 4000\u00a0mg q.d.s. (\n                      <jats:italic>n\u00a0<\/jats:italic>\n                      =\n                      <jats:italic>\u00a0<\/jats:italic>\n                      21), aspirin 325\u00a0mg q.d.s. (\n                      <jats:italic>n\u00a0<\/jats:italic>\n                      =\n                      <jats:italic>\u00a0<\/jats:italic>\n                      19) or paracetamol 4000\u00a0mg q.d.s. and aspirin 325\u00a0mg q.d.s. (\n                      <jats:italic>n\u00a0<\/jats:italic>\n                      =\n                      <jats:italic>\u00a0<\/jats:italic>\n                      20). Upper gastrointestinal mucosal injury was evaluated after 7\u00a0days of treatment with\n                      <jats:styled-content style=\"fixed-case\">TN<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">EGD<\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The rate of gastric ulcers in subjects receiving paracetamol (0\/21, 0%) alone or aspirin (3\/19, 16%) or both (2\/20, 10%) was not different. There were, however, significantly more subjects with one or more lesions (erosion or ulcer) per subject in the paracetamol and aspirin (16\/20, 80%) treated subjects as compared to the aspirin (8\/19, 42%,\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      &lt;\n                      <jats:italic>\u00a0<\/jats:italic>\n                      0.001) or the paracetamol (3\/21, 14%,\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      &lt;\n                      <jats:italic>\u00a0<\/jats:italic>\n                      0.01) exposed subjects. The mean number of lesions per subject was also greater (7.9 vs. 0.7,\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      &lt;\n                      <jats:italic>\u00a0<\/jats:italic>\n                      0.01) in those treated with aspirin and paracetamol compared to paracetamol alone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Co\u2010administration of paracetamol and aspirin was not associated with a significant difference in endoscopic ulcer rates compared to either drug alone. There was a strong signal for increased endoscopic erosions and ulcers in the combined group compared to either aspirin or paracetamol alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1365-2036.2012.05200.x","type":"journal-article","created":{"date-parts":[[2012,6,29]],"date-time":"2012-06-29T05:37:52Z","timestamp":1340948272000},"page":"391-397","source":"Crossref","is-referenced-by-count":7,"title":["Does concomitant use of paracetamol potentiate the gastroduodenal mucosal injury associated with aspirin? A prospective, randomised, pilot study"],"prefix":"10.1111","volume":"36","author":[{"given":"J. R.","family":"Boike","sequence":"first","affiliation":[{"name":"Department of Digestive Diseases and Nutrition University of Illinois at Chicago Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kao","sequence":"additional","affiliation":[{"name":"Department of Digestive Diseases and Nutrition University of Illinois at Chicago Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Digestive Diseases and Nutrition University of Illinois at Chicago Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Markle","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Illinois at Chicago Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Illinois at Chicago Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Niebruegge","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Illinois at Chicago Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. C.","family":"Stein","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Illinois at Chicago Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Berkes","sequence":"additional","affiliation":[{"name":"Department of Digestive Diseases and Nutrition University of Illinois at Chicago Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. L.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Department of Digestive Diseases and Nutrition University of Illinois at Chicago Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,6,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.10.001"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.02.013"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.310.6983.827"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02248.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1247"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.191087"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21596"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00091-6"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200510000-00009"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200109000-00018"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.00327.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01650.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(94)70068-0"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl.2008.2.3.155"},{"key":"e_1_2_6_16_1","first-page":"658","article-title":"Transnasal esogastroduodenoscopy (EGD): comparison with conventional EGD and new applications","volume":"138","author":"Maffei M","year":"2008","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_6_17_1","unstructured":"National Collaborating Centre for Chronic Conditions.Osteoarthritis: the care and management of osteoarthritis in adults.National Institute for Health and Clinical Excellence Feb 2008. Available at:http:\/\/publications.nice.org.uk\/osteoarthritis-cg59. Accessed May 1 2012."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00207-6"},{"key":"e_1_2_6_19_1","first-page":"1081","article-title":"Gastroduodenal complications of chronic NSAID therapy","volume":"83","author":"Graham DY","year":"1988","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05096.x"},{"key":"e_1_2_6_21_1","unstructured":"Food and Drug Administration.FDA limits acetaminophen in prescription combination products; requires liver toxicity warnings. January 2011. Available at:http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm239894.htm. Accessed May 1 2012."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.36013"},{"issue":"1","key":"e_1_2_6_23_1","first-page":"S140","article-title":"Outcomes studies of the gastrointestinal safety of cyclooxygenase\u20102 specific inhibitors","volume":"69","author":"Scheiman JM","year":"2002","journal-title":"Cleve Clin J Med"},{"issue":"25","key":"e_1_2_6_24_1","first-page":"S23","article-title":"NSAIDs and COX\u20102 inhibitors: what we can learn from large outcomes trials? The gastroenterologist's perspective","volume":"19","author":"Hawkey CJ","year":"2001","journal-title":"Clin Exp Rheumatol"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2012.05200.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2012.05200.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T08:02:20Z","timestamp":1700553740000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2012.05200.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,29]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1111\/j.1365-2036.2012.05200.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05200.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717950076.793455333","asserted-by":"object"}]},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,29]]}}}